Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Vomiting 1Sarcoma, Alveolar Soft Part 1Neurotoxicity Syndromes 1Nausea 1Hematologic Neoplasms 1Delirium 1

Interventions

Paclitaxel 3Amifostine 3Vincristine 2Procarbazine 2haloperidol decanoate 1axicabtagene ciloleucel 1Thalidomide 1Tadalafil 1Surveys and Questionnaires 1SLI381 1Rituximab 1Radiotherapy 1Prednisolone 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Modafinil 1Methylphenidate 1Methotrexate 1Melphalan 1Lorazepam 1Leucovorin 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1Glutamine 1Gene Expression Profiling 1Folfox protocol 1Fluorouracil 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurotoxicity Syndromes × Lorazepam × Clear all
NCT01949662 2026-02-13

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
93 enrolled 14 charts
Other hematologic neoplasm

Delirium, Hematologic Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡